Login to Your Account



Regenerative Medicine Play Hits Snag

Shire's Dermagraft Fails in VLU Only Months After ABH Buyout

By Jennifer Boggs


Friday, August 26, 2011
Only two months after Shire plc shelled out $750 million in cash for Advanced BioHealing Inc. – a move hailed as a rare win for investors in the regenerative medicine space – the big pharma reported disappointing data from a pivotal trial aimed at expanding the use of ABH's lead product Dermagraft.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription